Revolution Medicines, Inc. (RVMD)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-06) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-25) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-06) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-07) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-26) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-07) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-26) · 99.1 | 8-K (2024-01-09) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-06) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Statements of Operations (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Comprehensive Loss (unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Stockholders' Equity (deficit) (P) | — |
|
| Consolidated Statements of Stockholders' Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Acquisition | ||
| Available-for-sale Securities | ||
| Balance Sheet Components | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Convertible Senior Notes | — |
|
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Fair Value Measurements | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets and Goodwill | ||
| Liability Related To The Sale of Future Royalties | ||
| Net Loss Per Share Attributable To Common Stockholders | ||
| Organization | ||
| Pay Vs Performance Disclosure | ||
| Sanofi Collaboration Agreement | ||
| Stock-based Compensation | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Term Loan Facility | ||
| Warrant Liability | — |
|